Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

License Agreement with Yuhan Corporation (Details Narrative) - USD ($)				12 Months Ended
	Oct. 06, 2020	Aug. 19, 2020	Aug. 19, 2020	Dec. 31, 2020
Proceeds from offering				$ 4,625,948
License Agreement [Member] \| Yuhan Corporation [Member]
Number of common stock issued during period			250,000	500,000
Milestone payments, description		In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter into.
Performance of milestone conditions, description		Specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product within 48 months.
License Agreement [Member] \| Yuhan Affiliate [Member] \| Underwritten Public Offering [Member] \| October 2020 [Member]
Shares issued in connection with our 2020 offering	750,000
Proceeds from offering	$ 3,000,000